In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1

8 April 2024 (09:40 - 09:52)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Saranda Nimani

University of Bern, Bern (Switzerland)

4 More presentations in this session

Presentation thumbnail

Accelerated pacing reduces left heart filling pressures: a novel therapy for heart failure with preserved ejection fraction?

Mr T. Van Loon (Maastricht, NL)

Abstract Slides Video

Presentation thumbnail

The right atrium affects in silico arrhythmia vulnerability in both atria

Ms P. Martinez Diaz (Karlsruhe, DE)

Abstract Slides Video

Presentation thumbnail

Revealing intracavitary catheter positions: artificial intelligence-enhanced localization with an electrogram-driven variational autoencoder model

Mr G. Rios-Munoz (Madrid, ES)

Abstract Slides Video

Presentation thumbnail

Reduced heart failure hospitalizations and improved quality of life in cardiac amyloidosis patients undergoing atrial fibrillation ablation

Doctor N. Pierucci (Barcelona, ES)

Abstract Slides Video

Access the full session

Session thumbnail

Young Investigator Award Basic and Translational Science

The Event

Event poster

EHRA 2024

8 April 2024 09:40 CET

You may be interested in

Congress Presentation

Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits

Congress Presentation

Gene therapy approaches to restore normal cardiac repolarisation and prevent arrhythmias in QT syndromes

Congress Presentation

In vivo KCNQ1-suppression-replacement gene therapy in transgenic LQT1 rabbits restores a physiological QT interval at baseline and under catecholamine infusion

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources